Is dasatinib-related pulmonary hypertension a clinical concern?
Department of Pulmonary Circulation & Thromboembolic Diseases, Centre of Postgraduate Medical Education, European Health Centre, Otwock, Poland.
Sebastian
S
Szmit
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000069439:Dasatinib / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D006976:Hypertension, Pulmonary / Q000209:etiology* / Q000378:metabolism; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy / Q000401:mortality; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D000069439:Dasatinib
cardio-oncology; dasatinib; pleural effusion; pulmonary hypertension; sildenafil